ALVAC-CEA vaccine
ALVAC-CEA vaccine is a cancer vaccine containing a canary pox virus (ALVAC) combined with the carcinoembryonic antigen (CEA) human gene.
A phase I trial in 118 patients showed safety in humans.[1]
References
- Kaufman, Howard L.; Lenz, Heinz-Josef; Marshall, John; Singh, Deepti; Garett, Chris; Cripps, Christine; Moore, Malcolm; von Mehren, Margaret; Dalfen, Richard; Heim, William J.; Conry, Robert M.; Urba, Walter J.; Benson, Al B.; Yu, Maria; Caterini, Judy; Kim-Schulze, Seunghee; Debenedette, Mark; Salha, Danielle; Vogel, Thorsten; Elias, Ileana; Berinstein, Neil L. (2008). "Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer". Clinical Cancer Research. 14 (15): 4843–4849. doi:10.1158/1078-0432.CCR-08-0276. PMID 18676757. S2CID 18152383.
External links
- ALVAC-CEA vaccine entry in the public domain NCI Dictionary of Cancer Terms
This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.